Haemonetics Corp

In Stage 2 advance, HAE exhibits a constructive uptrend with higher highs and higher lows supported by rising short-term EMAs and favorable volume. However, price is currently extended above dynamic EMAs and the options score indicates overbought conditions, warranting patience for a pullback into support before engaging. Medium-term bias remains bullish despite moderate transition risk, while near-term timing is unfavorable for immediate entry.

• ↑Q4 2026 revenue $346M (+5% YoY; +9% organic ex-CSL)
• ↑Adjusted EPS rose 4% to $1.29; free cash flow $210M (89% conversion)
• ↓Interventional technologies revenue declined 5% in Q4, signaling segment risk